See a thymosin alpha 1 dosage chart with typical research ranges, weight-based dosing math, and route comparisons, plus safety notes for US readers.
There is no official thymosin alpha 1 dosage chart for the United States, because the peptide is not FDA-approved for human use here. The most-cited human research protocols used 1.6 mg injected subcutaneously twice weekly, while wellness-oriented protocols commonly list 0.5 mg to 1.5 mg per dose, two or three times per week. Every chart below summarizes published trials and community practice, not a medical recommendation.
Why There Is No Single Official Thymosin Alpha 1 Dosage Chart
Thymosin alpha 1 is a synthetic version of a thymic peptide involved in T-cell maturation. The prescription form, sold as Zadaxin, is approved in more than 30 countries, including Italy, Japan, and Singapore, for conditions such as chronic hepatitis B and as a vaccine adjuvant. In the United States, thymosin alpha 1 remains an unapproved research peptide, so no regulator publishes a standard dose.
Charts also disagree because they pull from very different sources. A labeled dose in a hepatitis B trial is not the same thing as a self-reported wellness schedule posted on a forum.
- Labeled use: fixed 1.6 mg doses, no weight adjustment.
- Clinical trials: sometimes daily, sometimes twice weekly, depending on the disease studied.
- Community protocols: lower doses, longer maintenance schedules, and frequent off-label stacking.
- Route: subcutaneous injection, nasal spray, or (rarely) oral capsules, each with very different absorption.
Researchers comparing protocols often start with a general thymosin alpha 1 overview before drilling into numbers, which is why dose tables vary so widely.
Thymosin Alpha 1 Dosage Chart: Common Ranges in Research
The table below collects the dose ranges most often cited in human studies and in community write-ups. Treat it as a reference point for understanding how protocols are built, not as a personal plan.
| Context | Typical dose | Frequency | Route |
|---|---|---|---|
| Labeled use (chronic hepatitis B, Zadaxin) | 1.6 mg | Twice weekly | Subcutaneous |
| Hepatitis C combination trials | 1.6 mg | Twice weekly for 6–12 months | Subcutaneous |
| Sepsis and immune-suppression research | 1.6 mg | Study-specific, often daily for several days | Subcutaneous |
| Community maintenance protocols | 0.5–1.5 mg | 2–3 times per week | Subcutaneous |
| Self-reported nasal use | 0.25–1 mg per nostril | Daily or every other day | Intranasal |
| Weight-based math | 0.02–0.05 mg/kg | Varies by protocol | Subcutaneous |
Weight-Based Dosing and Dosage Calculators
A thymosin alpha-1 dosage calculator usually applies a milligram-per-kilogram formula to body weight. That approach is common in peptide research, but it matters less here than people assume, because the labeled 1.6 mg dose is not weight-adjusted to begin with.
For a 70 kg adult, 1.6 mg works out to roughly 0.023 mg/kg. That number already sits inside the 0.02–0.05 mg/kg band many calculators use, so a calculator often returns the same figure the original trials used.
Weight-based charts are more useful for peptides where exposure tracks body mass. A bpc-157 dosage chart by weight is a familiar example, and a mots-c dosage chart typically splits ranges by lean body mass rather than total weight. A selank dosage chart, by contrast, usually lists micrograms per dose, which is why comparing peptide charts side by side can be misleading without checking the units.
Thymosin Alpha 1 Dosage When Sick
Search interest in a thymosin alpha 1 dosage when sick reflects a real question: do short, higher-frequency courses make sense at the first sign of illness? The honest answer is that no controlled human trial has tested thymosin alpha 1 as an acute cold or flu treatment, so any "sick day" protocol is extrapolated from immune-adjuvant research.
Community write-ups often describe 1.6 mg daily for three to five days, then a return to twice-weekly maintenance. Some people use lower doses, and some use none at all.
- Fever, severe fatigue, or breathing trouble needs a medical evaluation, not a peptide.
- Short courses are not automatically safer than maintenance dosing just because they are brief.
- Anyone taking immunosuppressants or with an autoimmune condition should talk to a clinician before using immune-modulating peptides.
How to Take Thymosin Alpha 1: Injection vs. Nasal Spray
Route changes both the dose and the reliability of that dose. Subcutaneous injection is the route used in every major human trial, and it delivers the peptide into tissue where it is absorbed predictably. Nasal use avoids needles but has never been validated in a controlled absorption study.
| Route | Typical range | What to know |
|---|---|---|
| Subcutaneous injection | 1.6 mg (labeled) or 0.5–1.5 mg (community) | Reconstituted powder, insulin syringe, rotating injection sites |
| Nasal spray | 0.25–1 mg per nostril | Absorption and stability are unverified; reported thymosin alpha 1 nasal spray dosage varies widely |
| Oral capsules | Not established | Peptides are generally broken down in the digestive tract |
If a vial arrives as lyophilized powder, it must be reconstituted with bacteriostatic water before injection. Because the concentration depends on how much water is added, two vials of the same peptide can produce very different doses per unit on a syringe.
Safety, Side Effects, and Legal Status
Reported side effects in trials were usually mild and included injection-site irritation, fatigue, and flu-like symptoms. Long-term safety data beyond roughly 12 months of treatment are limited.
Thymosin alpha 1 is not FDA-approved for human use in the United States, and it is sold there as a research chemical rather than a regulated drug. That means purity, concentration, and sterility are not verified by the FDA.
People who are pregnant, breastfeeding, or being treated for cancer or autoimmune disease should not experiment with dosing schedules on their own. A healthcare professional can review interactions and whether an approved therapy would be a better fit.
Frequently Asked Questions
What is the typical thymosin alpha 1 dosage?
Most published human trials used 1.6 mg injected subcutaneously twice weekly. Community protocols commonly fall between 0.5 mg and 1.5 mg per dose, two or three times per week. Because thymosin alpha 1 is not FDA-approved in the United States, no official US dose exists.
Is thymosin alpha 1 approved by the FDA?
No. Thymosin alpha 1 is not FDA-approved for human use in the United States. The synthetic version sold as Zadaxin is approved in several other countries, including Italy and Japan, for conditions such as chronic hepatitis B. In the US it is typically sold as a research chemical, so purity and dosing are not verified by regulators.
Can you take thymosin alpha 1 as a nasal spray instead of an injection?
Nasal use is common in the wellness community, with self-reported doses around 0.25 mg to 1 mg per nostril per day. No human trials have established how much of that dose is actually absorbed, so nasal dosing is far less predictable than subcutaneous injection. Injection remains the only route studied in controlled human research.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.